Introduction
============

Maintenance of oxygen homeostasis is a fundamental physiological challenge. Dysregulation of homeostasis with a consequent hypoxia is a component of many human diseases. Transcriptional response to hypoxia is mediated by hypoxia inducible factors (HIF1--3), the oxygen-sensitive signal being generated by a series of protein hydroxylases that catalyze prolyl and asparaginyl hydroxylation on specific residues in the regulatory HIF-α subunits (HIF1α, HIF-2α, and HIF-3α). Mammalian HIF-α subunits contain two hydroxylation sites called NODD (N-terminal Oxygen-dependant Degradation Domain) and CODD (C-terminal Oxygen-dependant Degradation Domain). In the presence of oxygen, prolyl hydroxylation by prolyl hydroxylase domain proteins (PHD1--4) directs HIF-α for proteasome destruction following binding by the product of the tumor suppressor gene von Hippel--Lindau (pVHL) and ubiquitination ([Figure 1](#f1-hp-5-011){ref-type="fig"}).[@b1-hp-5-011],[@b2-hp-5-011] In addition, asparaginyl hydroxylation by factor inhibiting HIF (FIH) blocks recruitment of HIF co-factors. The HIF hydroxylases belong to two distinct groups of Fe(II)- and 2-oxoglutarate (2-OG)-dependent dioxygenase, which split O2 and couple oxidation (hydroxylation) of HIF-α to oxidative decarboxylation of 2-OG to succinate and CO~2~. PHD2, in particular, has been described to play a dominant role in oxygen sensing.[@b3-hp-5-011],[@b4-hp-5-011] In the absence of oxygen, hydroxylases are inhibited, HIF-α factors are stabilized, enter the nucleus, and associate with HIF-β subunits (ie, aryl hydrocarbon receptor nuclear translocators ARNT1 or ARNT2) and cofactors (p300). These complexes form active transcription factors that bind hypoxia responsive elements (HREs) and drive the expressions of more than hundred target genes.[@b5-hp-5-011],[@b6-hp-5-011] These transcripts encode proteins that play a role in multiple biological pathways (cell survival, erythropoiesis, angiogenesis, metabolism, etc).[@b7-hp-5-011],[@b8-hp-5-011] The panel of genes expressed in different cell types is specific, and their regulation by different HIF isoforms is complex and still puzzling. In the meeting, Prof P Ratcliffe and Prof I Ragoussis presented recent pan-genomic studies that revealed some aspects of the hypoxia pathway complexity.

Complexity of the Hypoxia pathway
=================================

Complex HIF hydroxylase modulation and transcriptional architecture of HIF-1α versus HIF-2α binding
---------------------------------------------------------------------------------------------------

Prof P Ratcliffe provided an overview of the HIF hydroxylase pathway and considered opportunities and challenges in its therapeutic modulation, specifically whether it might be possible (and advantageous) to modulate specific components of the pathway under specific clinical settings. The evolution of the HIF prolyl hydroxylase pathway was outlined, highlighting the primitive PHD2/HIF-1α/VHL triad.[@b9-hp-5-011] Of particular relevance to the question of specific therapeutic modulation is the appearance of multiple HIF and PHD isoforms, through gene duplication events at the base of vertebrate evolution.[@b10-hp-5-011] This raises a question as to what extent these different isoforms have particular functions in the specialized oxygen delivery systems (the blood, vascular, and cardiopulmonary systems) of vertebrates, which are often the target of diseases. As a paradigm, the question of whether PHD inhibition could generate medically useful, isoform specific, activation of HIF-1α versus HIF-2α was considered.

Although the differential regulation of HIF-α isoforms is not completely understood, they demonstrate differential dependence on each of two prolyl hydroxylation sites in the N-terminal and C-terminal portions of their oxygen-dependent degradation domains (NODD and CODD).[@b11-hp-5-011] Thus, inhibitors that operate differentially on the hydroxylation of each of these sites might impart at least partial HIF-α isoform selectivity. Initial evidence that this might be possible has been provided by the action of human mutations in PHD2, some of which generate striking differences in hydroxylation of HIF-1α NODD versus CODD.[@b12-hp-5-011] The feasibility of generating relatively specific inhibitors is also supported by differences in the binding of human NODD and CODD to PHD2[@b12-hp-5-011] and from the ability of some, but not all, PHD inhibitors to displace CODD substrate as well as 2-OG from PHD2.[@b13-hp-5-011] All the PHDs, and \~60--70 other human dioxygenases in this family, use 2-OG as co-substrate; hence, inhibitors that simply act as 2-OG analogs are unlikely to be highly specific.[@b14-hp-5-011] Thus, it was argued that greater efforts would be required to develop substrate specific inhibitors and that at least some selectivity would likely be feasible.

In light of this, recent work on the functional differentiation of HIF-1α versus HIF-2α was considered from two contrasting perspectives: 1) transcriptional biology, as assessed by pan-genomic assays of the HIF transcriptional response using ChIPseq and RNAseq analyses, and 2) the integrated physiology of hypoxia, assessed in recombinant mice bearing inactivating alleles of HIF-1α and HIF-2α.

As an example of HIF-α isoform-specific actions on integrated physiology, recent work on erythropoiesis and ventilator sensitivity to hypoxia was considered.[@b15-hp-5-011],[@b16-hp-5-011] Increased erythropoiesis and enhanced ventilator sensitivity to hypoxia are key physiological components of the process of acute acclimatization. Direct comparison of conditional inactivation of HIF-1α with HIF-2α in adult life (as a surrogate for potential actions of specific pharmacological intervention) reveals marked specificity for the HIF-2α isoforms, at least under the conditions of experimental testing.[@b15-hp-5-011],[@b16-hp-5-011] This is consistent with, and likely in part driven by, contrasting patterns of expression. HIF-2α is expressed at much higher levels in the renal erythropoietin-producing fibroblasts and in the type 1 cells of the carotid body.[@b17-hp-5-011],[@b18-hp-5-011] Thus, it might be concluded that specific activation of HIF-2α would be of value in therapeutic strategies that aimed to augment these responses (ie, in the correction of anemia or in the stimulation of ventilation).

As a counterpoise to this work, recent insights into the transcriptional biology of HIF were then considered from the perspective of pan-genomic studies that contrast patterns of HIF1α and HIF-2α at transcriptional target loci. These studies have defined distinct, though partially overlapping, sets of DNA binding sites for HIF-1α and HIF-2α.[@b19-hp-5-011] Depending on the level of analytical stringency applied, each isoform binds at hundreds to a few thousand sites, at levels sufficient to have an effect on transcription. No differences for HIF-1α versus HIF-2α are seen in consensus binding sequences. However, marked differences are observed across the genome in the distribution of binding at \>10^6^ potential hypoxia response elements in open chromatin. Gene ontology programs define differences in the functional pathways associated with gene loci that preferentially bind HIF-1α or HIF-2α, but these are generally not tightly demarcated; rather moderate pathway bias is observed in one or other isoform.[@b20-hp-5-011] Interestingly, significant biases are also observed in the type of transcriptional target, with HIF-2α showing greater enrichment than HIF-1α at loci associated with long non-coding RNAs.[@b21-hp-5-011] However, the most striking differences are observed in the distance between the HIF-α binding sites and gene promoters.[@b20-hp-5-011],[@b22-hp-5-011] HIF-1α is much more frequently bound close to promoters, with HIF-2α being more commonly bound at a distance from promoters. Moreover, even when both the HIF-α isoforms bound close to a promoter, functional studies reveal that it is generally HIF-1α that mediates the transcriptional response.[@b23-hp-5-011] Thus, when considered both are considered at the level of transcriptional biology and in the setting of integrated physiology, HIF-2α manifests features consistent with it being the "modern" isoform. HIF-2α mediates several of the adaptive responses to hypoxia that are specific to higher animals; it binds and functions at greater distances from its target genes, its expression is more cell-type specific, and it exhibits more frequent interactions with non-coding RNA networks. However, none of these properties is absolutely specific.

In the discussion, it was speculated that this lack of clear organization was a fundamental reflection of Darwinian evolution, in which mutations are generated agnostically and alter specific biochemical processes, but selection is applied to the performance of integrated physiological systems. This process runs counter to the aim of dissecting highly specific drug targets out of complex systems. The conclusions were that the development of more specific HIF hydroxylase inhibitors, which target components of the HIF pathway with moderate levels of selectivity, would be feasible. Nevertheless, accurate predictions about what might or might not be useful in a specific medicinal situation remain difficult. The development of multiple inhibitors with diverse kinetic and chemical properties, coupled careful testing in physiological models, and (ideally) human experimental medicine studies, would be an ideal approach to this new area of medicine development.

Complex expression of genes in hypoxia identified by RNAseq
-----------------------------------------------------------

A major part of the adaptive response to hypoxia is mediated through transcriptional regulation, with the HIF transcription factors taking central stage. As presented by Prof I Ragoussis, the detailed study of the transcriptional response is conditional upon developing and applying genomic technologies that allow the global characterization of a wide universe of transcripts in the cell. Methodological developments utilizing the power of short read next generation sequencing technology have been applied, which allow the analysis of long and short transcripts following the removal of the highly abundant ribosomal RNA, while also retaining information on transcriptional orientation. Thus, for the first time, it was possible to identify global transcriptional changes under hypoxia in all classes of coding and non-coding RNAs, including small RNAs.[@b21-hp-5-011] As a result, our understanding of the transcriptional response to hypoxia is greatly enhanced and now covers the entire spectrum of RNAs, coding and non-coding, regulatory, microRNAs, t-RNAs, small nuclear RNAs, and others. In addition, through the integration of ChIP data produced using antibodies against HIF-1α, HIF-2α, HIF-1β, and PolII as well as the histones H3K4Me3 and H3K4me1, it was possible to determine that poised PolII is localized at the promoters of both coding and non-coding transcripts, the increased transcription of which is associated with HIF binding.[@b21-hp-5-011] More recently, this binding has been determined to take place at pre-existing promoter, promoter--enhancer, and enhancer--enhancer interactions using chromatin conformation assays.[@b23-hp-5-011] The role of long non-coding RNAs in hypoxia response is now the focus of intense research.[@b24-hp-5-011] Typical examples include HIF-2α regulated lncRNA NEAT1 that leads to the identification of paraspeckle formation as a response to hypoxia[@b25-hp-5-011] in breast cancer cells, whereas H19 is found to play a role in cell cycle in hypoxic HUVEC cells.[@b26-hp-5-011]

There is good evidence that alternative splicing contributes to a substantial part of the hypoxic response and is also directly regulated by HIF and can lead to the production of non-coding mRNA isoforms implicated in upregulated genes.[@b27-hp-5-011]--[@b30-hp-5-011] Sena et al[@b27-hp-5-011] observed a dichotomy between high frequency of exon inclusion in hypoxia up-regulated genes, whereas exon exclusion was found predominant in downregulated genes using HEP3B cells. Following that, Memon et al[@b29-hp-5-011] observed that there is a major switch to non-coding isoforms in hypoxic HTCC116 human colon carcinoma cells, which was recapitulated in a large set of colorectal cancer samples from TCGA. More work is needed in a wider range of tissues and cancers in order to confirm the observations related to HIF's role in splicing, the trends related to up- or down-regulated transcripts and any pathway-specific splicing effects, but it is clear that alternative splicing plays a major role in the hypoxia response.

In terms of technological developments, inferring alternatively spliced isoforms of genes from short read data through statistical assignment of the most probable combination of exons is still computationally challenging and not very accurate. New, single molecule sequencing technologies are now enabling the direct sequencing of complete cDNA or even RNA molecules and their application[@b31-hp-5-011],[@b32-hp-5-011] has the potential to allow the characterization of the hypoxia transcriptome at even higher resolution.

Hypoxia pathway in physiology and therapies
===========================================

In the meeting, sessions were dedicated to the physiological aspects of hypoxia. In fact, the physiological reaction to low oxygen induces adaptation and is essential to cell survival. As described earlier, the HIFs induce the expression of hundred of genes that play roles in many biological pathways.

Role on glucose and lipid metabolism
------------------------------------

Prof P Koivunen presented HIF target genes and use of mouse models to study the connection of HIF with glucose and lipid metabolism. In agreement with a key role of hypoxia in lipid metabolism, genetic inhibition of *Phd2* has recently been shown to reduce body weight and the amount of white adipose tissue (WAT) in mice.[@b33-hp-5-011] These mice hypomorphic for *Phd2* also had smaller adipocytes, less WAT inflammation, and better glucose tolerance, and did not develop insulin resistance when fed with high-fat diet (HFD) or aged.[@b33-hp-5-011] Moreover, they had lowered serum cholesterol levels and an improved high density lipoprotein (HDL)/low density lipoprotein (LDL) + very low density lipoprotein (VLDL) cholesterol ratio and were protected against steatohepatitis.[@b33-hp-5-011] The molecular-level determinants of the phenotype were upregulation of the HIF-1α target *Glut1* and *Glut4* mRNAs, several enzymes of glycolysis and *Pdk1* mRNA in several tissues, downregulation of some inflammatory mRNAs in WAT and upregulation of the insulin sensitivity increasing, HIF2α target *Irs2* mRNA and the concomitant downregulation of the lipogenesis regulating *Srebp1c* mRNA and its downstream targets *Fas*, *Acca*, and *Scd1* in the liver.[@b33-hp-5-011],[@b34-hp-5-011] Mice deficient for *Phd2* in adipose tissue also showed resistance to HFD-induced obesity and had a better glucose tolerance.[@b35-hp-5-011] In another study, knockout of *Phd2* in adipocytes blunted lipolysis and increased intracellular lipid storages, therefore reducing ectopic lipid deposition.[@b36-hp-5-011] When wild-type mice were treated with a pharmacological PHD inhibitor FG-4497, obesity and metabolic syndrome opposing phenotype was observed.[@b33-hp-5-011] In support of these data, clinical trials with two different PHD inhibitors, FG-4592 (Roxadustat) and GSK1278863, for the treatment of anemia and peripheral vascular disease, respectively, report lowered serum cholesterol levels and an improved HDL/LDL profile with the subjects treated with the inhibitors.[@b37-hp-5-011],[@b38-hp-5-011] Dyslipidemia and metabolic syndrome predispose to atherosclerosis. Recent data from mice associate inhibition of PHDs 1 and 2 with protection against atherosclerosis.[@b34-hp-5-011],[@b39-hp-5-011] The mechanisms involved were HIF-mediated modifications to metabolism including that for cholesterol, reduced inflammation, and beneficial alterations to the immune system.[@b34-hp-5-011],[@b39-hp-5-011] Although metabolic syndrome and the connected diseases are highly associated with life style only a minority of patients succeed in its improvement and end up in medication. Recent data provide evidence for justification to explore PHD inhibitors and activation of the endogenous hypoxia response pathway, to treat obesity, metabolic dysfunction, and atherosclerosis.

Role on musculoskeletal system
------------------------------

Prof J Myllyharju presented another example of the physiological role of the hypoxia pathway, related to the regulation of extracellular matrix homeostasis.[@b40-hp-5-011] The presentation focused on the roles of collagen prolyl 4-hydroxylases (C-P4Hs) and lysyl oxidase (LOX) in the musculoskeletal system. Indeed, HIF induces the expression of several key enzymes such as CP4Hs, lysyl hydroxylases, and LOX that are required for proper collagen synthesis and assembly, and hence correct structure and function of connective tissues.[@b41-hp-5-011],[@b42-hp-5-011] Remodeling of extracellular matrix by these collagen-modifying enzymes has recently been shown to be important in hypoxic cancer metastasis.[@b43-hp-5-011],[@b44-hp-5-011] C-P4Hs are essential enzymes for collagen synthesis as the modifications catalyzed by these enzymes are required for thermal stability of collagens at body temperature. The C-P4H family consists of three isoenzymes, C-P4Hs I and II being the major forms.[@b41-hp-5-011] CP4H-I is expressed ubiquitously, whereas C-P4H-II has a more restricted expression pattern, being a prominent form in for example chondrocytes and osteoblasts.[@b41-hp-5-011] It has been shown that HIF-1α-regulated induction of C-P4Hs is necessary for sufficient collagen production in a hypoxic tissue environment such as, for example, in the cartilage chondrocytes.[@b45-hp-5-011] Studies with gene-modified mice lines have shown that *c-P4h-1*^−/−^mice die during early embryogenesis because of nonfunctional assembly of collagen IV into basement membranes.[@b46-hp-5-011] Reduced C-P4H activity in *c-P4h-1*^+/−^/*c-P4h-2*^−/−^double mutant mice leads to several connective tissue abnormalities. These include abnormal development of cartilage and bone resulting in structural and biomechanical impairment of these tissues and chondrodysplasia.[@b47-hp-5-011] Similar, but much milder abnormalities are present in the *c-P4h-2*^−/−^single mutant mice.[@b47-hp-5-011] As no signs of uncompensated endoplasmic reticulum stress were observed in these mice, the main cause of the chondrodysplasia is likely to be aberrant mechanosensing and signaling cues mediated by the abnormal extracellular matrix.[@b47-hp-5-011] Another collagen-modifying enzyme highly induced by HIF is LOX that catalyzes crosslink formation in collagen fibrils and elastin and affects the maturation, turnover, and stiffness of connective tissue.[@b42-hp-5-011] LOX is the major isoenzyme of the LOX family.[@b42-hp-5-011] It has been shown that lack of LOX interferes with the development of several connective tissues resulting in dysfunction of the cardiovascular and respiratory systems, aortic aneurysms, and perinatal lethality in mouse.[@b48-hp-5-011],[@b49-hp-5-011] Interestingly, it has been shown recently that muscle composition is regulated by a LOX--TGFβ feedback loop. Lack of LOX was found to lead to excess expression of TGFβ that disrupts the balance between the amounts of myofibers and that of muscle connective tissue.[@b50-hp-5-011] This results in short and small muscles with reduced amount of myofibers and abnormal muscle patterning.[@b50-hp-5-011] Remarkably, this abnormal muscle development could be rescued by TGFβ inhibition.[@b50-hp-5-011] The regulatory effect of LOX on TGFβ signaling may be explained by either direct interaction between LOX and TGFβ or its receptor and/or increased susceptibility of insufficiently crosslinked collagens and elastin to proteolysis, which could result in elevated liberation of TGFβ from the extracellular matrix reservoir of the *Lox*^−/−^ tissue.[@b50-hp-5-011]

Hypoxia pathway in pathology and therapies
==========================================

The meeting dedicated a session to the pathological aspect of hypoxia. The oxygen-sensing pathway may be dysregulated with a consequent constitutive activation of HIF transcription factors and target genes expression as observed, for example, in many types of tumors. The hypoxia pathway participates and sometimes initiates progression of a vast majority of tumors. The causes of HIF stabilization are wide-ranging, from a chronic hypoxic microenvironment to mutations in direct key regulator genes. The causes may also be indirect with the inhibition of hydroxylases by the production of 2-OG mimetics (following mutations in metabolic enzymes) or by oxidation (modification of the redox status, oxidation of co-factors, etc).

Example of chondrosarcoma
-------------------------

Prof J Bovée presented chondrosarcomas as an example of tumors linked to hypoxia. Chondrosarcoma is the second most frequent primary bone malignancy, predominantly affecting adults. They usually arise from their benign precursor lesions: 1) peripheral chondrosarcoma arising in osteochondroma (at the surface of bone, with mutations in exostosin genes *EXT1* or *EXT2* encoding glycosyltransferases involved in heparan sulphate biosynthesis) and 2) central chondrosarcoma arising in enchondroma (in the medulla of bone, with mutations in isocitrate dehydrogenase genes *IDH1* or *IDH2*). The prognosis is strongly correlated with histological grading. Grade I chondrosarcoma, now reclassified as an atypical cartilaginous tumor, is poorly vascularized, behaves locally aggressive, but typically does not metastasize. High-grade chondrosarcomas (grades II and III) have an increased vascularity and increased metastases corresponding to poor patient survival. Surgery is the mainstay of treatment. If the tumor location is non-resectable or metastatic, there is still no curative treatment.[@b51-hp-5-011],[@b52-hp-5-011] Chondrosarcoma is notorious for its primary resistance to conventional chemo- and radiotherapy. [@b51-hp-5-011],[@b53-hp-5-011] A multistep genetic model has been devised: while specific mutations (*IDH*, *EXT*) cause the benign precursor lesions, high-grade chondrosarcomas have complex karyotypes[@b54-hp-5-011] with many additional mutations.[@b50-hp-5-011] Since cartilaginous tissue as well as chondrosarcomas has a hypoxic microenvironment,[@b55-hp-5-011] it has been hypothesized that hypoxia is involved in chondrosarcoma aggressiveness, and this is supported by the increased microvessel density, vascular endothelial growth factor (VEGF), and HIF-1α levels in high-grade chondrosarcoma as compared to low grade.[@b56-hp-5-011],[@b57-hp-5-011] Interestingly, mutations in the *IDH* genes are found in up to 80% of enchondromas and \~50% of chondrosarcomas. IDH is involved in the tricarboxylic acid cycle. Mutations in IDH lead to the formation of a neoenzyme that catalyzes the reduction of 2-OG to D-2-hydroxyglutarate (D2HG),[@b58-hp-5-011] which is considered an oncometabolite and inhibits some α ketoglutarate dependent oxygenases. Regarding the effect of D2HG on prolyl hydroxylase and HIF pathway, mutations in *IDH* were first shown to associate with stabilization of HIF-1α,[@b59-hp-5-011] but later it was shown that D2HG produced by these mutations is not a potent PHD inhibitor.[@b60-hp-5-011],[@b61-hp-5-011] An inhibitory effect of D2HG has been demonstrated on the dioxygenase tenelevan-translocation-2 (TET2),[@b62-hp-5-011] a dioxygenase that catalyzes hydroxylation of methylated DNA. This results in inhibition of DNA demethylation, causing hypermethylation,[@b62-hp-5-011],[@b63-hp-5-011] and altered histone[@b60-hp-5-011] that impacts tumor progression.

Example of Mn porphyrin-based redoxactive drugs as anticancer therapeutics
--------------------------------------------------------------------------

Some aspects of anticancer therapies have been presented during the meeting. Notably, Prof I Batinic-Haberle focused on manganese (Mn) porphyrin-based superoxide dismutase (SOD) mimics as anticancer therapeutics. Porphyrins are molecules that comprise the active site of numerous key enzymes (hemoglobin, myoglobin, prolyl hydroxylase, cyt P450 oxidases, nitric oxide synthases, oxygenases, etc). These enzymes contain macrocyclic protoporphyrin ring that encapsulates iron and affords extreme stability to iron complex.

Batinic-Haberle, Spasojevic, Tovmasyan, and other collaborators have developed very stable and redox-active manganese porphyrins (MnPs) as powerful mimics of superoxide dismutase (SOD) family of enzymes.[@b64-hp-5-011]--[@b66-hp-5-011] They have mimicked the nature in its use of iron protoporphyrin as active site of different proteins to run major metabolic functions such as oxygen transport and detoxification among those. Yet, instead of protoporphyrin bound to iron, MnP-based SOD mimics have *N*-substituted pyridylporphyrins bound to manganese. MnPs exhibit remarkable ability to protect normal tissue from radiation (RT)-induced damage, such as brain, salivary glands, mouth mucosa, colon, eye, prostate, hematopoietic stem cells, and lung. Moreover, MnPs are powerful tumor radio-and chemosensitizers as demonstrated with lymphoma and tumors of brain, breast, head and neck, ovary, and prostate. Based on differential properties of MnPs to protect normal while killing cancerous tissues, two lead compounds, MnTE-2-PyP^5+^ and MnTnBuOE-2-PyP^5+^, progressed to Phase I/II clinical trials, the latter at Duke University.

MnPs as mimics of superoxide family of enzymes also react with numerous other reactive species (RS) such as peroxynitrite (ONOO^−^), nitric oxide (.NO), and hypochlorite (ClO^−^) (reviewed in[@b64-hp-5-011]--[@b66-hp-5-011]). The actions of MnPs are also H~2~O~2~-driven and are frequently coupled with cellular reductants such as ascorbate, glutathione (GSH), and protein thiols. Although they have insignificant catalase-like activity, MnPs possess GSH peroxidase and thiol oxidase-like activities. The magnitude of all actions of MnPs thus far studied, including SOD-like activity, parallels the magnitude of their therapeutic efficacies and is dependent upon the metal-centered reduction potential of Mn^III^P/Mn^II^P redox couple; in turn the magnitude of those actions parallels each other. In addition to reacting with different RS, MnPs inhibit activities of several transcription factors, such as HIF-1α, NF-κB, AP-1, SP-1, and Nrf2, thereby affecting cellular apoptotic and proliferative pathways.[@b64-hp-5-011]--[@b66-hp-5-011] The nature of such interactions has mostly been explored with respect to NF-κB and has been ascribed to MnP-catalyzed and H~2~O~2~/GSH-driven oxidation/*S*-glutathionylation of thiols in its p50 and p65 subunits. Preliminary data also indicate the major role of Nrf2 in the actions of MnPs.

MnPs exhibit differential effects to normal and tumor tissues presumably by impacting NFκB/HIF-1α/Nrf2 pathways.[@b64-hp-5-011]--[@b66-hp-5-011] The HIF and NF-κB pathways are closely related. Hypoxia contributes to the development of inflammation, at least in part through the activation and/or potentiation of NF-κB, a master regulator of genes involved in innate immunity, inflammation, and apoptosis.[@b67-hp-5-011],[@b68-hp-5-011] The differential effects of MnPs on these pathways arise from different redox environments and diverse accumulation of MnPs in those tissues. In normal cells/tissues, MnPs reduce inflammation. For example, in a rat pulmonary radioprotection study, MnPs suppressed RT-induced lung inflammation through the inhibition of HIF-1α activation and downregulation of its target gene VEGF, which seemed to be controlled by NF-κB.[@b69-hp-5-011],[@b70-hp-5-011]

The cancer cell, though, relative to the normal cell, has excessive levels of endogenous H~2~O~2~, and thereby is often under oxidative stress and sensitive to any further increase in oxidative stress. This is due to its perturbed redox environment, often with increased MnSOD levels but insufficient levels and/or activities of peroxide-removing enzymes.[@b64-hp-5-011]--[@b66-hp-5-011] Such situation has been heavily exploited in anticancer therapies, one of which includes MnP alone and/or combined with exogenously imposed oxidative stress. MnP, when administered at high concentration, exhibited an anticancer effect in its own right in a 4T1 breast cancer mouse model,[@b71-hp-5-011] where large inhibition of HIF-1α activity (presumably orchestrated through oxidation and subsequent inactivation of NF-kB) contributed to the suppression of angiogenesis. In the same model, the anticancer effect of MnP was further enhanced when it was given jointly with exogenous sources of H~2~O~2~ -- RT, chemotherapy, or ascorbate.[@b64-hp-5-011] Furthermore, the massive MnP/H~2~O~2~/GSH-driven suppression of anti-apoptotic NF-κB was demonstrated in a cellular lymphoma model where lymphoma cells were exposed to MnP and dexamethasone.[@b69-hp-5-011],[@b72-hp-5-011] In addition, complexes I and III of mitochondrial respiration were *S*-glutathionylated, and in turn inactivated, resulting in the loss of ATP.

The excessive tumor H~2~O~2~ levels, along with up to 10-fold higher accumulation of MnPs in tumor than in normal tissue[@b73-hp-5-011] -- as major reactants in a process of *S*-gluthathionylation -- drive higher tumor yield of NF-κB oxidation relative to normal tissue. Consequently, apoptotic processes are favored in the tumor, whereas a suppression of inflammation occurs in normal tissue ([Figure 2](#f2-hp-5-011){ref-type="fig"}).[@b66-hp-5-011]

Drugs, commonly known as antioxidants/vitamins, such as ascorbate, tocopherols, and carotenoids, have been tested in clinical trials as single anticancer drugs with only marginal effect. The lack of effect is still not fully understood. Batinic-Haberle et al have contributed recently to the understanding of why that maybe so.[@b63-hp-5-011],[@b73-hp-5-011] In order to affect cancer cell metabolism, the redox active drug needs to inhibit anti-apoptotic pathways. It seems that such inhibition does not happen primarily by removing RS, as thought for a long while, but instead by using RS to oxidize signaling protein cysteines. The major function of ascorbate under physiological conditions is to protect tocopherol; it cycles with oxidized tocopherol radical thereby regenerating tocopherol. Yet at higher levels, achieved if added exogenously, ascorbate cycling with endogenous metal complexes (such as cyt P450 oxidases) will result in a large production of cytotoxic H~2~O~2~, which in turn will oxidize and inactivate thiols of critical cellular proteins (such as NF-κB and complexes I and III of mitochondrial respiration). In turn, tumor growth may be moderately suppressed. Yet, a massive anticancer effect could be achieved with increased yield of protein oxidation, when additional source(s) of H~2~O~2~ (RT and chemotherapy) and/or catalyst, optimized for ascorbate oxidation (such as MnTE-2-PyP^5+^ or MnTnBuOE-2PyP^5+^), are applied ([Figure 2](#f2-hp-5-011){ref-type="fig"}).[@b69-hp-5-011],[@b72-hp-5-011]--[@b74-hp-5-011]

Conclusion
==========

This meeting covered large themes of the hypoxia field and highlighted the complexity of the oxygen sensing pathway. It opened discussion about perspectives to better understand its role in physiology and disease occurrence and to specifically target it for therapies.
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![Schematic representation of the hypoxia regulation pathway.\
**Abbreviations:** 2-OG, 2-oxoglutarate; 2-HG, 2-hydroxyglutarate; 2-OGDDs, 2-oxoglutarate-dependent dioxygenases; IDH, isocitrate dehydrogenase; FH, fumarate hydratase; SDH, succinate dehydrogenase; PHD, prolyl hydroxylase domain protein; VHL, von Hippel--Lindau; HIF, hypoxia inducible factor; alt.splicing, alternative splicing; SOD, superoxide dismutase.](hp-5-011Fig1){#f1-hp-5-011}

![Differential redox environments of cancer versus normal cells drive differential therapeutic outcomes.\
**Notes:** In tumor cells compared to normal cells, MnSOD is frequently upregulated, whereas peroxide-removing enzymes are downregulated or inactive, which gives rise to higher H~2~O~2~ levels resulting in higher oxidative stress. When anticancer therapies that further enhance tumor oxidative stress, such as redox-active drugs (MnP) in combination with radiation, and/or chemotherapy and/or ascorbate, are applied, the differential effects are observed in normal (suppression of inflammation leading to tissue healing) versus cancerous tissue (death). Adapted from *Redox-Active Therapeutics*. Mn porphyrin-based redox-active therapeutics. 2016:165--212. Batinić-Haberle I, Tovmasyan A, Spasojević I. © 2016, with permission of Springer.[@b66-hp-5-011]\
**Abbreviations:** SOD, superoxide dismutase; HA^−^, ascorbate; HA•, ascorbyl radical; CAT, catalase; GPx, glutathione peroxidase; Prx, peroxiredoxin; O~2~•^−^, superoxide; O~2~, oxygen; H~2~O~2~, hydrogen peroxide; Mn^III^P and Mn^II^P, Mn porphyrin with manganese center in oxidized (+3) or reduced (+2) form, respectively.](hp-5-011Fig2){#f2-hp-5-011}
